Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Medtronic

This article was originally published in The Gray Sheet

Executive Summary

Medtronic: Receives FDA go-ahead to market its Jewel Plus Active Can (Model 7220C) implantable-cardioverter-defibrillator, the company announces May 10. The 34-joule device incorporates Medtronic's Flashback memory feature, which Medtronic says "provides key information about the history and onset of tachyarrhythmia episodes," and the firm's Marker Channel technology, which "aids precise diagnosis by indicating device response." In addition, the device features a "new interval plotting capability (graphic display of episode characteristics) for stored tachyarrhythmia episodes," the firm says. Medtronic also releases commercially its Transvene tined silicone lead (Model 6934S), which it says is the "world's first tachyarrhythmia lead employing a steroid-eluting electrode to minimize scar-tissue formation at the endocardial wall and thus enhance sensing performance"...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT005973

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel